TEGSEDI study
Brief description of study
This research study is being done at the request of the US Food & Drug Administration (FDA) to collect additional safety information for the commercially available drug TEGSEDI. This research study is being conducted to examine any changes in health or side effects occurring within 24 hours following treatment with TEGSEDI. This is a post-marketing safety study, subjects with hATTR Amyloidosis with Polyneuropathy who receive commercially available TEGSEDI will be enrolled in the study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
TEGSEDI study
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female 18 years of years or older Diagnosed with hATTR-PN and prescribed TEGSEDI
Updated on
09 Mar 2024.
Study ID: 844001
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
